M
Mousumi Som
Researcher at Oklahoma State University–Stillwater
Publications - 2
Citations - 338
Mousumi Som is an academic researcher from Oklahoma State University–Stillwater. The author has contributed to research in topics: Context (language use) & Population. The author has an hindex of 2, co-authored 2 publications receiving 45 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Vincent C. Marconi,Vincent C. Marconi,Athimalaipet V Ramanan,Stephanie de Bono,Cynthia E. Kartman,Venkatesh Krishnan,Ran Liao,Maria Lucia B. Piruzeli,Jason D Goldman,Jorge Alatorre-Alexander,Rita de Cassia Pellegrini,Vicente Estrada,Mousumi Som,Anabela Cardoso,Sujatro Chakladar,Brenda J. Crowe,Paulo Reis,Xin Zhang,David H. Adams,E. Wesley Ely +19 more
TL;DR: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties as discussed by the authors, which has been shown to reduce mortality in hospitalised adults with COVID-19.
Posted ContentDOI
Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19
Vincent C. Marconi,Athimalaipet V Ramanan,Stephanie de Bono,Cynthia E. Kartman,Venkatesh Krishnan,Ran Liao,Maria Lucia B. Piruzeli,Jason D Goldman,Jason D Goldman,Jorge Alatorre-Alexander,Rita de Cassia Pellegrini,Vicente Estrada,Mousumi Som,Anabela Cardoso,Sujatro Chakladar,Brenda J. Crowe,Paulo Reis,Xin Zhang,David H. Adams,E. Wesley Ely +19 more
TL;DR: The COVID-BARRIER trial as discussed by the authors evaluated the efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC) in hospitalised adults with COVID19.